1-6 of 6
Keisuke Shirai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO-035: Immune profiles of long-term survivors of patients with head and neck squamous carcinoma on immune checkpoint inhibitor therapy

Free
Brock Christensen, Min Kyung Lee, Ze Zhang, Rondi Butler, Geat Ramush, Kartik Sehgal, Keisuke Shirai, Devin Koestler, Lucas Salas, John Wiencke, Robert Haddad, Karl Kelsey
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PO-035.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-035
Published: 15 September 2023
View articletitled, Abstract PO-035: Immune profiles of long-term survivors of patients with head and neck squamous carcinoma on immune checkpoint inhibitor therapy
Journal Articles

Abstract PO-048: Baseline blood DNA methylation-based immune profiles are associated with survival outcomes in head and neck cancer patients on immune checkpoint therapy

Free
Ze Zhang, Kartik Sehgal, Keisuke Shirai, Rondi Butler, Min Kyung Lee, Annette Molinaro, John Wiencke, Devin Koestler, Hannah Stolrow, Geat Ramush, Lucas Salas, Robert Haddad, Karl Kelsey, Brock Christensen
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PO-048.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-048
Published: 15 September 2023
View articletitled, Abstract PO-048: Baseline blood DNA methylation-based immune profiles are associated with survival outcomes in head and neck cancer patients on immune checkpoint therapy
Journal Articles

Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial

Available to Purchase
Terry A. Day, Keisuke Shirai, Paul E. O'Brien, Maria Gisele Matheus, Kristina Godwin, Amit J. Sood, Anvesh Kompelli, Julie A. Vick, Daniel Martin, Lynn Vitale-Cross, Juan Luis Callejas-Varela, Zhiyong Wang, Xingyu Wu, Olivier Harismendy, Alfredo A. Molinolo, Scott M. Lippman, Carter Van Waes, Eva Szabo, J. Silvio Gutkind
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1156–1164.
https://doi.org/10.1158/1078-0432.CCR-18-2024
Published: 15 February 2019
View articletitled, Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Open the PDF for Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors

Available to Purchase
Carolyn D. Britten, Elizabeth Garrett-Mayer, Steven H. Chin, Keisuke Shirai, Besim Ogretmen, Tricia A. Bentz, Alan Brisendine, Kate Anderton, Susan L. Cusack, Lynn W. Maines, Yan Zhuang, Charles D. Smith, Melanie B. Thomas
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (16): 4642–4650.
https://doi.org/10.1158/1078-0432.CCR-16-2363
Published: 14 August 2017
View articletitled, A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors in another window
Journal Articles

Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response

Available to Purchase
Sahar A. Saddoughi, Elizabeth Garrett-Mayer, Uzair Chaudhary, Paul E. O'Brien, Larry B. Afrin, Terry A. Day, M. Boyd Gillespie, Anand K. Sharma, Christina S. Wilhoit, Robin Bostick, Can E. Senkal, Yusuf A. Hannun, Jacek Bielawski, George R. Simon, Keisuke Shirai, Besim Ogretmen
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (18): 6097–6105.
https://doi.org/10.1158/1078-0432.CCR-11-0930
Published: 14 September 2011
View articletitled, Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response
Open the PDF for Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response in another window
Journal Articles

Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma

Available to Purchase
Christopher J. Herrem, Tomohide Tatsumi, Kathleen S. Olson, Keisuke Shirai, James H. Finke, Ronald M. Bukowski, Ming Zhou, Amy L. Richmond, Ithaar Derweesh, Michael S. Kinch, Walter J. Storkus
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (1): 226–231.
https://doi.org/10.1158/1078-0432.226.11.1
Published: 21 January 2005
View articletitled, Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma
Open the PDF for Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma in another window